GlassScriptPhysician profile
Irene L Cueto
NPI 1629001482
$3,528.16
in general payments reported to CMS, 2019-2025
7 companies · $225 in 2025
The $225 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $124 · 2021: $621 · 2022: $876 · 2023: $971 · 2024: $711 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,907.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,235.07 | 2020-2025 | Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $597.40 | 2022-2023 | Farxiga, Breztri, Fasenra |
| Novo Nordisk INC | $269.64 | 2022-2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $189.44 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $121.54 | 2021 | |
| Antares Pharma, INC. | $86.48 | 2024-2025 | Xyosted |
| Halozyme INC | $28.59 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irene Cueto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.